Amikacin Afortas
Aminoglycoside antibiotic injection for serious gram-negative bacterial infections
Amikacin Afortas is a prescription aminoglycoside antibiotic administered by injection for the treatment of serious bacterial infections. It is particularly effective against gram-negative bacteria, including multidrug-resistant strains such as Pseudomonas aeruginosa. Amikacin is used when other antibiotics have failed or when the infecting organism is resistant to less toxic agents. Treatment requires close medical supervision with regular monitoring of kidney function and drug blood levels due to the risk of nephrotoxicity and ototoxicity.
Quick Facts
Key Takeaways
- Amikacin Afortas is a powerful aminoglycoside antibiotic reserved for serious, life-threatening bacterial infections resistant to other treatments.
- It is always administered in a hospital or clinical setting via intravenous infusion or intramuscular injection — never taken orally.
- Therapeutic drug monitoring is essential: blood levels must be checked regularly to ensure efficacy and prevent toxicity.
- The most significant risks include kidney damage (nephrotoxicity) and irreversible hearing loss (ototoxicity), both of which are dose-related.
- Treatment courses are typically 7–10 days; prolonged use increases the risk of serious adverse effects.
What Is Amikacin Afortas and What Is It Used For?
Amikacin belongs to the aminoglycoside class of antibiotics, a group of drugs that have been a cornerstone of antimicrobial therapy since the 1940s. Amikacin was specifically developed as a semi-synthetic derivative of kanamycin to overcome many of the resistance mechanisms that bacteria had developed against earlier aminoglycosides such as gentamicin and tobramycin. Its unique chemical structure makes it resistant to most aminoglycoside-modifying enzymes produced by resistant bacteria, which gives it a broader spectrum of activity than many other drugs in its class.
The mechanism of action of amikacin is concentration-dependent and bactericidal. It works by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts the normal process of protein synthesis by causing the bacterial ribosome to misread the genetic code carried by messenger RNA (mRNA). As a result, the bacterium produces defective, nonfunctional proteins that are incorporated into its cell membrane, leading to increased permeability, cellular damage, and ultimately bacterial death. This concentration-dependent killing means that higher peak concentrations relative to the minimum inhibitory concentration (MIC) of the bacterium result in more effective killing.
Amikacin also demonstrates a clinically significant post-antibiotic effect (PAE), meaning that bacterial growth remains suppressed even after the drug concentration falls below the MIC. This pharmacodynamic property supports the increasingly adopted practice of extended-interval (once-daily) dosing, which maximizes the peak concentration while allowing trough levels to fall, thereby reducing the risk of toxicity. Clinical studies and meta-analyses, including those published in the Cochrane Database, have demonstrated that once-daily aminoglycoside dosing is at least as effective as traditional multiple-daily dosing and may be associated with less nephrotoxicity.
Indications and Clinical Uses
Amikacin Afortas is indicated for the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria. Specific clinical indications include:
- Septicemia (bloodstream infections): Including bacteremia caused by gram-negative organisms, particularly in immunocompromised patients or those in intensive care settings.
- Serious respiratory tract infections: Hospital-acquired pneumonia and ventilator-associated pneumonia (VAP) caused by susceptible organisms, often used in combination with a beta-lactam antibiotic.
- Complicated urinary tract infections (UTIs): Pyelonephritis and urosepsis caused by multidrug-resistant gram-negative pathogens.
- Bone and joint infections: Osteomyelitis and septic arthritis caused by susceptible gram-negative organisms.
- Skin and soft tissue infections: Including burn wound infections and post-surgical wound infections with gram-negative pathogens.
- Intra-abdominal infections: Peritonitis and other abdominal infections, typically as part of a combination regimen.
- Central nervous system infections: Bacterial meningitis and ventriculitis caused by susceptible gram-negative organisms, sometimes administered intrathecally or intraventricularly in addition to systemic therapy.
- Endocarditis: As part of combination therapy for gram-negative bacterial endocarditis.
Amikacin is particularly valued in clinical practice for its activity against multidrug-resistant (MDR) gram-negative bacteria, including strains that produce extended-spectrum beta-lactamases (ESBLs) and some carbapenemase-producing organisms. The World Health Organization (WHO) classifies amikacin as a critically important antimicrobial for human medicine, and it is included on the WHO Model List of Essential Medicines, underscoring its importance in the global antimicrobial arsenal.
Amikacin should be reserved for serious infections when less toxic antimicrobial agents are not appropriate. It is not suitable for mild or self-limiting infections. Bacterial culture and sensitivity testing should guide the choice of antibiotic therapy whenever possible.
What Should You Know Before Taking Amikacin Afortas?
Amikacin Afortas is a potent antibiotic that requires careful patient assessment before initiation. The drug carries significant risks of nephrotoxicity and ototoxicity, and these risks are compounded by pre-existing conditions, concurrent medications, and patient-specific factors such as age and renal function. A thorough medical history and baseline investigations are essential before starting treatment.
Contraindications
Amikacin Afortas should not be used in patients with:
- Known hypersensitivity: Patients with a documented allergy to amikacin, any other aminoglycoside antibiotic (gentamicin, tobramycin, streptomycin, neomycin), or any of the excipients in the formulation. Cross-sensitivity among aminoglycosides is well documented.
- Myasthenia gravis: Aminoglycosides can exacerbate neuromuscular blockade and may precipitate a myasthenic crisis. This is an absolute contraindication unless the infection is life-threatening and no alternative exists.
Warnings and Precautions
Healthcare professionals should exercise particular caution when prescribing amikacin in the following situations:
- Renal impairment: Patients with pre-existing kidney disease or reduced creatinine clearance are at significantly increased risk of nephrotoxicity. Dose adjustments based on creatinine clearance are mandatory, and more frequent monitoring of serum drug levels and renal function is required. The drug is primarily eliminated by glomerular filtration, and impaired renal function leads to drug accumulation.
- Pre-existing hearing loss or vestibular dysfunction: Aminoglycoside ototoxicity can be irreversible. Patients with baseline auditory or vestibular deficits should undergo audiometric testing before and during treatment. Cochlear damage typically affects high-frequency hearing first and may progress even after the drug is discontinued.
- Elderly patients: Age-related decline in renal function (which may not be reflected by serum creatinine alone) puts elderly patients at higher risk. Dose adjustments based on estimated glomerular filtration rate (eGFR) or creatinine clearance are essential.
- Dehydration and hypovolemia: Volume depletion increases the risk of nephrotoxicity by reducing renal perfusion. Adequate hydration should be ensured before and during amikacin therapy.
- Burns patients: Patients with extensive burns may have altered pharmacokinetics, including increased volume of distribution and enhanced renal clearance, requiring higher or more frequent dosing guided by therapeutic drug monitoring.
- Concurrent nephrotoxic or ototoxic drugs: Concomitant use with other nephrotoxic or ototoxic agents significantly increases the risk of adverse effects. These drugs include vancomycin, amphotericin B, cisplatin, cyclosporine, and loop diuretics such as furosemide.
- Neuromuscular disorders: In addition to myasthenia gravis, caution is warranted in patients with Parkinson's disease or other conditions affecting neuromuscular function, as aminoglycosides can potentiate neuromuscular blockade.
Amikacin can cause irreversible bilateral hearing loss, vestibular toxicity, and kidney damage. The risk increases with higher doses, longer treatment duration, pre-existing renal impairment, and concurrent use of other nephrotoxic/ototoxic drugs. Therapeutic drug monitoring, regular audiometry, and kidney function tests are essential throughout treatment. Report any changes in hearing, tinnitus, dizziness, or reduced urine output to your healthcare team immediately.
Pregnancy and Breastfeeding
Amikacin crosses the placental barrier and may cause fetal harm, particularly ototoxicity. Aminoglycosides have been associated with irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy, and similar risks are assumed for all aminoglycosides including amikacin. The drug should only be used during pregnancy when the potential benefit clearly justifies the risk to the fetus, and no safer alternative is available. Women of childbearing potential should be counseled about these risks.
Amikacin is excreted in breast milk in small amounts. Because aminoglycosides are poorly absorbed from the gastrointestinal tract, systemic exposure in the nursing infant is expected to be minimal. However, potential effects on the infant's gastrointestinal flora should be considered. A decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother and the potential risk to the infant.
How Does Amikacin Afortas Interact with Other Drugs?
Drug interactions with amikacin are a critical concern because many of the interacting drugs are commonly used in the same clinical settings (intensive care, oncology, transplant medicine) where amikacin is prescribed. Understanding these interactions is essential for safe prescribing and monitoring. The interactions are primarily pharmacodynamic (additive toxicity) rather than pharmacokinetic, though some pharmacokinetic interactions exist.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Vancomycin | Additive nephrotoxicity and ototoxicity; significantly increased risk of acute kidney injury | Monitor renal function daily; monitor drug levels of both agents; ensure adequate hydration |
| Amphotericin B | Synergistic nephrotoxicity; both drugs cause renal tubular damage | Avoid combination if possible; if essential, monitor renal function and electrolytes daily |
| Cisplatin | Additive nephrotoxicity and ototoxicity; may cause permanent hearing loss | Avoid combination; if unavoidable, perform baseline and serial audiometry; monitor renal function closely |
| Furosemide (loop diuretics) | Increased ototoxicity risk; diuretic-induced dehydration increases nephrotoxicity | Monitor hearing; ensure adequate fluid replacement; avoid rapid IV administration of furosemide |
| Neuromuscular blocking agents (e.g., succinylcholine, vecuronium) | Potentiation of neuromuscular blockade; risk of prolonged respiratory paralysis | Use with extreme caution in surgical settings; have calcium chloride and neostigmine available for reversal |
| Cyclosporine | Additive nephrotoxicity; elevated serum creatinine | Monitor renal function and cyclosporine levels frequently; consider alternative antibiotic |
Minor Interactions
The following interactions are generally less severe but should still be noted:
- Penicillins and cephalosporins: When mixed in the same IV line or syringe, beta-lactam antibiotics can chemically inactivate aminoglycosides. However, the combination is often synergistic when administered separately and is a common therapeutic strategy for serious infections like endocarditis. Always administer amikacin and beta-lactam antibiotics through separate IV lines or at different times.
- NSAIDs (non-steroidal anti-inflammatory drugs): Ibuprofen, diclofenac, and other NSAIDs may reduce renal blood flow and impair aminoglycoside elimination, potentially increasing drug accumulation and toxicity risk.
- ACE inhibitors and ARBs: These antihypertensive drugs can reduce renal perfusion, particularly in patients with renal artery stenosis, potentially impairing amikacin clearance.
- Radiocontrast agents: Iodinated contrast media used in CT scans and angiography can cause contrast-induced nephropathy, and the combination with amikacin increases the cumulative nephrotoxic burden. Adequate hydration and a waiting period between contrast administration and amikacin dosing are advisable.
Amikacin must never be mixed with other antibiotics (especially penicillins and cephalosporins) in the same intravenous solution or syringe. Chemical incompatibility leads to inactivation of the aminoglycoside, reducing its therapeutic efficacy. Always use separate IV lines or flush the line thoroughly between infusions.
What Is the Correct Dosage of Amikacin Afortas?
Dosing of amikacin requires individualization based on the patient's body weight, renal function, severity of infection, and the susceptibility of the causative organism. The trend in modern clinical practice, supported by meta-analyses and guidelines from the Infectious Diseases Society of America (IDSA) and the British National Formulary (BNF), favors extended-interval (once-daily) dosing for most patients. This approach takes advantage of the concentration-dependent killing and post-antibiotic effect of aminoglycosides while potentially reducing toxicity.
Adults
Standard Dosing – Adults with Normal Renal Function
- Extended-interval (once-daily) dosing: 15–20 mg/kg IV once daily, infused over 30–60 minutes. This is the preferred regimen for most patients.
- Traditional (multiple-daily) dosing: 15 mg/kg/day IV or IM, divided into 2–3 equal doses every 8–12 hours (i.e., 5–7.5 mg/kg per dose).
- Maximum daily dose: 1.5 g/day (not to be exceeded regardless of body weight).
- Duration: 7–10 days; longer courses may be required for endocarditis or osteomyelitis but carry increased toxicity risk.
| Patient Group | Dose | Frequency | Key Considerations |
|---|---|---|---|
| Adults (normal renal function) | 15–20 mg/kg | Once daily (IV) | Use ideal body weight for non-obese; adjusted body weight for obese patients |
| Adults (renal impairment) | Adjusted per CrCl | Extended intervals | Dose reduce and/or extend interval based on creatinine clearance; TDM essential |
| Neonates | 15 mg/kg | Every 24–48 hours | Extended interval due to immature renal function; TDM mandatory |
| Children (1 month–12 years) | 15–20 mg/kg | Once daily (IV) | Children may require higher mg/kg doses due to larger volume of distribution |
| Elderly (>65 years) | Based on CrCl | Adjusted intervals | Age-related renal decline; use CrCl not serum creatinine alone; more frequent TDM |
| Obese patients (BMI >30) | Based on adjusted BW | Once daily | Use adjusted body weight: IBW + 0.4 × (actual BW − IBW) |
Children
In pediatric patients, amikacin dosing is weight-based and must account for the age-dependent differences in pharmacokinetics. Neonates have a larger volume of distribution and reduced renal clearance compared to older children, necessitating extended dosing intervals. Children older than one month typically receive 15–20 mg/kg once daily, similar to adult extended-interval dosing. In all pediatric age groups, therapeutic drug monitoring is essential to ensure adequate drug exposure while minimizing toxicity.
Elderly
Elderly patients require careful dose adjustment because age-related decline in glomerular filtration rate (GFR) may not be reflected by serum creatinine levels alone. Creatinine clearance should be estimated using validated formulas (such as Cockcroft-Gault) or measured directly. Lower doses and/or extended dosing intervals are often necessary. More frequent therapeutic drug monitoring is recommended, with particular attention to trough levels to prevent drug accumulation and toxicity.
Missed Dose
Because amikacin is administered in a hospital setting under medical supervision, missed doses are uncommon. If a dose is inadvertently missed, it should be administered as soon as possible, and the subsequent dose should be scheduled based on therapeutic drug monitoring results. The dosing interval should not be shortened to "catch up," as this increases the risk of toxicity. Your healthcare team will adjust the dosing schedule as needed.
Overdose
Amikacin overdose is a serious medical emergency. Symptoms of overdose may include acute kidney failure, ototoxicity (hearing loss, tinnitus, vertigo), and neuromuscular blockade leading to respiratory paralysis. Treatment is primarily supportive: maintain airway and ventilation, aggressive intravenous fluid resuscitation, and correction of electrolyte imbalances. Hemodialysis is effective in removing amikacin from the blood and should be considered in cases of severe overdose, particularly in patients with renal impairment. Peritoneal dialysis is less effective than hemodialysis for aminoglycoside removal.
For extended-interval dosing, a random serum level drawn 6–14 hours after the dose is used with a nomogram to determine the appropriate dosing interval. For traditional dosing, target peak levels are 20–35 mcg/mL (drawn 30 minutes after IV infusion) and trough levels should be <5 mcg/mL (drawn just before the next dose). TDM should be performed after the second or third dose and at least twice weekly during treatment.
What Are the Side Effects of Amikacin Afortas?
Like all aminoglycoside antibiotics, amikacin has a relatively narrow therapeutic index, meaning the margin between therapeutic and toxic concentrations is small. The frequency and severity of adverse effects are influenced by the total cumulative dose, duration of treatment, peak and trough serum concentrations, patient's renal function, age, hydration status, and concomitant use of other nephrotoxic or ototoxic drugs. Careful therapeutic drug monitoring and clinical vigilance are essential to minimizing adverse effects.
Very Common (>1/10)
- Nephrotoxicity – elevated serum creatinine and blood urea nitrogen (BUN), typically reversible if detected early and drug is stopped promptly
- Injection site reactions – pain, induration, or phlebitis at the IV infusion site
Common (1/10 to 1/100)
- Ototoxicity – cochlear damage (high-frequency hearing loss, tinnitus) and/or vestibular damage (dizziness, vertigo, nystagmus, ataxia)
- Electrolyte disturbances – hypomagnesemia, hypocalcemia, hypokalemia due to renal tubular wasting
- Nausea and vomiting
- Elevated liver enzymes (transient)
Uncommon (1/100 to 1/1,000)
- Neuromuscular blockade – muscle weakness, respiratory depression (particularly risk in patients with myasthenia gravis or receiving anesthesia)
- Skin rash, urticaria, or drug fever
- Headache
- Tremor or paresthesia (numbness/tingling)
Rare (<1/1,000)
- Anaphylaxis or severe hypersensitivity reaction
- Acute renal failure requiring dialysis
- Complete bilateral sensorineural hearing loss (usually after prolonged use or high cumulative doses)
- Agranulocytosis or other blood dyscrasias
- Pseudomembranous colitis (Clostridioides difficile infection)
Nephrotoxicity is the most common clinically significant adverse effect, occurring in 5–25% of patients depending on risk factors and monitoring protocols. The mechanism involves accumulation of amikacin in the proximal renal tubular cells, leading to cellular damage and impaired tubular function. Early signs include a rising serum creatinine and the presence of tubular casts in the urine. Nephrotoxicity is usually reversible if detected early and the drug is discontinued or the dose adjusted, though recovery may take several weeks.
Ototoxicity affects both the cochlear (hearing) and vestibular (balance) systems. Cochlear toxicity typically manifests as high-frequency hearing loss that may progress to lower frequencies with continued exposure. Vestibular toxicity presents as dizziness, vertigo, nystagmus, and ataxia. Unlike nephrotoxicity, ototoxicity is often irreversible because it results from destruction of the sensory hair cells of the inner ear, which do not regenerate. Patients should be instructed to report any changes in hearing, ringing in the ears (tinnitus), or balance disturbances immediately.
Contact your healthcare team immediately if you experience any of the following while receiving amikacin: sudden hearing loss or ringing in the ears; dizziness or loss of balance; significant decrease in urine output; muscle weakness or difficulty breathing; severe skin rash or signs of allergic reaction (swelling of face, lips, or throat); blood in urine. These symptoms may indicate serious toxicity requiring immediate intervention.
How Should You Store Amikacin Afortas?
Proper storage of amikacin is essential to maintain its potency, sterility, and safety. As a parenteral (injectable) medication, amikacin Afortas has specific storage requirements that must be followed by healthcare facilities and pharmacies handling the product. Patients do not typically handle this medication at home, as it is administered in clinical settings.
The intact vials of Amikacin Afortas solution for injection should be stored at room temperature, below 25°C (77°F). The product should be protected from light and must not be frozen. Freezing can alter the chemical stability and physical properties of the solution, potentially rendering it unsafe for administration. The vials should be stored in their original packaging until ready for use.
Once opened or diluted, the solution should be used promptly. If diluted for intravenous infusion, the diluted solution should be used within 24 hours when stored at room temperature (15–25°C) or within 48 hours if refrigerated (2–8°C), unless otherwise specified by the hospital pharmacy. Any unused portion of a single-use vial should be discarded immediately after use in accordance with local regulations for pharmaceutical waste disposal.
Before administration, the solution should be visually inspected for particulate matter and discoloration. Amikacin solution is normally colorless to pale yellow. Solutions that are deeply discolored or contain visible particles should not be used. Do not use the product if the seal is broken, the expiry date has passed, or the packaging appears damaged.
What Does Amikacin Afortas Contain?
Understanding the composition of Amikacin Afortas is important for identifying potential allergens and ensuring compatibility with other intravenous solutions. The formulation is designed for parenteral administration and must meet stringent pharmaceutical standards for sterility, endotoxin content, and chemical stability.
Active Ingredient
The active substance is amikacin, present as amikacin sulfate. Each milliliter of solution contains amikacin sulfate equivalent to 250 mg of amikacin base. Amikacin sulfate is the sulfate salt of amikacin, a semi-synthetic aminoglycoside antibiotic derived from kanamycin A. Its chemical name is O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy-alpha-D-glucopyranosyl-(1→4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine sulfate.
Excipients (Inactive Ingredients)
- Sodium citrate: Used as a buffering agent to maintain the pH of the solution within the optimal range for stability and tolerability.
- Sodium metabisulfite: An antioxidant preservative. Patients with sulfite sensitivity (more common in asthmatic individuals) may experience allergic reactions including bronchospasm. Healthcare providers should be aware of this excipient when prescribing to patients with known sulfite allergy.
- Sulfuric acid and/or sodium hydroxide: Used for pH adjustment to achieve the target pH of approximately 3.5–5.5.
- Water for injections: The solvent, meeting pharmacopoeial standards for sterility and endotoxin content.
Amikacin Afortas contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but is likely low; it is seen more frequently in asthmatic individuals. Inform your healthcare provider if you have a known sulfite allergy.
Frequently Asked Questions About Amikacin Afortas
References
All medical information on this page is based on peer-reviewed research and international clinical guidelines. The following sources were consulted:
- World Health Organization (WHO). Model List of Essential Medicines, 23rd list, 2023. Geneva: WHO. Available at: who.int
- European Medicines Agency (EMA). Amikacin – Summary of Product Characteristics (SmPC). Available at: ema.europa.eu
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America (IDSA) 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases. 2023;76(Suppl 2):e169–e233.
- Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312(7027):338–345. doi:10.1136/bmj.312.7027.338
- Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrobial Agents and Chemotherapy. 1999;43(7):1549–1555.
- British National Formulary (BNF). Amikacin monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Internal Medicine Journal. 2011;41(6):441–449. doi:10.1111/j.1445-5994.2011.02452.x
- Bland CM, Pai MP, Engemann JJ. Amikacin pharmacokinetics in the era of multidrug resistance. Pharmacotherapy. 2018;38(12):1279–1291.
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 14th Edition. McGraw-Hill Education, 2023. Chapter: Aminoglycosides.
- World Health Organization (WHO). Critically Important Antimicrobials for Human Medicine, 6th revision, 2019. Geneva: WHO.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with expertise in clinical pharmacology, infectious disease, and internal medicine.
iMedic Medical Editorial Team – Specialists in clinical pharmacology and antimicrobial therapy with documented academic background and clinical experience in infectious disease management.
iMedic Medical Review Board – Independent panel of board-certified physicians who verify all content against current international guidelines (WHO, EMA, FDA, IDSA, BNF) and the GRADE evidence framework.
All content on iMedic is evidence-based and reviewed by qualified medical professionals. We follow the GRADE framework for evidence assessment and adhere to international guidelines from WHO, EMA, FDA, and IDSA. We receive no commercial funding and have no conflicts of interest. Read more about our editorial standards.